A Study of Zidovudine in HIV-Infected Patients With Liver Disease

NCT00001001 | Completed

• 2 other identifiers: ACTG 06211036
• Study Type: interventional
• Target: 39
• Locations: 1 country
• Sites: 5

Brief Summary

To examine the pharmacokinetics (blood levels) and bioavailability of zidovudine (AZT) given to patients with HIV infection and chronic liver disease. The specific aim of the study is to provide data permitting the development of guidelines for use of AZT in patients with mild, moderate, or severe liver disease. AZT is the only antiviral agent that has been shown to be effective in patients with severe HIV infection. However, AZT is largely eliminated from the body through a biochemical reaction that takes place in the liver, and it is possible that patients with underlying liver disease may have altered AZT pharmacokinetics and may metabolize AZT differently, with the result that they are susceptible to an increased risk of serious drug toxicity. This study will examine the pharmacokinetics, elimination, and metabolism of AZT in patients with liver disease. Guidelines developed from the data will be helpful in managing AZT treatment of these HIV-infected persons and will indicate whether the dose of AZT administered should be adjusted to compensate for any changes in its bioavailability and/or pharmacokinetics.

Conditions

HIV Infections; Liver Diseases

Keywords

Liver; Liver Diseases; Liver Function Tests; HIV Seropositivity; Acquired Immunodeficiency Syndrome; Zidovudine; Biological Availability

Interventions

Zidovudine DRUG

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Concurrent Medication:
• Allowed after completion of day 2 of study:
• Prior medications may be resumed.
• Concurrent Treatment:
• Allowed after completion of day 2 of study:
• Cytotoxic chemotherapy or radiation therapy for Kaposi's sarcoma.
• The study will be divided into three groups of cooperative patients according to mild, moderate, or severe liver disease. Severity of disease will be assessed within 7 days of entry into the study according to laboratory values. Patients must have normal kidney function. No medications should be taken for 48 hours prior to entering the study. Hemophiliacs are included.
• Prior Medication:
• Allowed:
• Zidovudine (AZT) if discontinued at least 48 hours prior to study entry.

You may not qualify if:

• Co-existing Condition:
• Patients will be excluded from the study if unacceptable toxicity develops or if an illness requiring concurrent treatment develops.
• Concurrent Medication:
• Excluded within 48 hours of study entry:
• All medications. Medication may be resumed after completion of day 2 of the study.
• Concurrent Treatment:
• Excluded within 48 hours of study entry:
• All treatments. Treatment may be resumed after completion of day 2 of the study.
• Patients will be excluded for the following reasons:
• Presence of active opportunistic infections, with the exception of active or chronic hepatitis B virus or hepatitis D virus infection, or ongoing therapy for an opportunistic infection.
• Thrombocytopenia, with platelets less than 50000 platelets/mm3.
• Neutropenia, with polymorphonuclear leukocytes less than 1000 cells/mm3.
• Renal insufficiency, with creatinine greater than 1.5 mg/dl.
• Acute viral hepatitis within 30 days of the study.
• Patients who are expected to be noncompliant or who are unwilling to sign an informed consent statement.

Sponsors & Collaborators

• National Institute of Allergy and Infectious Diseases (NIAID): lead

Study Sites (5)

Boston Med Ctr

Boston, Massachusetts, 02118, United States

Location

Univ of Massachusetts Med Ctr

Worcester, Massachusetts, 01655, United States

Location

Univ of North Carolina

Chapel Hill, North Carolina, 275997215, United States

Location

Milton S Hershey Med Ctr

Hershey, Pennsylvania, 170330850, United States

Location

Univ of Washington

Seattle, Washington, 98105, United States

Location

Related Publications (1)

• Moore KH, Raasch RH, Brouwer KL, Opheim K, Cheeseman SH, Eyster E, Lemon SM, van der Horst CM. Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062). Antimicrob Agents Chemother. 1995 Dec;39(12):2732-7. doi: 10.1128/AAC.39.12.2732.

  PMID: 8593010 BACKGROUND

MeSH Terms

Conditions

HIV Infections; Liver Diseases; HIV Seropositivity; Acquired Immunodeficiency Syndrome

Interventions

Zidovudine

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases; Digestive System Diseases; Slow Virus Diseases

Intervention Hierarchy (Ancestors)

Thymidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Dideoxynucleosides; Deoxyribonucleosides; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides

Study Officials

• Lemon SM

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: not applicable
• Masking: NONE
• Purpose: TREATMENT
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 2, 1999
• First Posted: August 31, 2001
• Study Completion: May 1, 1990
• Last Updated: November 4, 2021

Record last verified: 2021-10

Locations

US (5)